SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors

A Citarella, A Scala, A Piperno, N Micale - Biomolecules, 2021 - mdpi.com
The uncontrolled spread of the COVID-19 pandemic caused by the new coronavirus SARS-
CoV-2 during 2020–2021 is one of the most devastating events in the history, with …

In vitro selection of macrocyclic peptide inhibitors containing cyclic γ2,4-amino acids targeting the SARS-CoV-2 main protease

T Miura, TR Malla, CD Owen, A Tumber, L Brewitz… - Nature Chemistry, 2023 - nature.com
Abstract γ-Amino acids can play important roles in the biological activities of natural
products; however, the ribosomal incorporation of γ-amino acids into peptides is …

Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists

S Zhang, M Krumberger, MA Morris… - European journal of …, 2021 - Elsevier
This paper describes the structure-based design of a preliminary drug candidate against
COVID-19 using free software and publicly available X-ray crystallographic structures. The …

Challenges of short substrate analogues as SARS-CoV-2 main protease inhibitors

S Ullrich, VM Sasi, MC Mahawaththa… - Bioorganic & Medicinal …, 2021 - Elsevier
Specific anti-coronaviral drugs complementing available vaccines are urgently needed to
fight the COVID-19 pandemic. Given its high conservation across the betacoronavirus genus …

A ricin-based peptide BRIP from Hordeum vulgare inhibits Mpro of SARS-CoV-2

P Kashyap, VK Bhardwaj, M Chauhan, V Chauhan… - Scientific Reports, 2022 - nature.com
COVID-19 pandemic caused by SARS-CoV-2 led to the research aiming to find the inhibitors
of this virus. Towards this world problem, an attempt was made to identify SARS-CoV-2 main …

Identification of a Putative SARS-CoV-2 Main Protease Inhibitor through In Silico Screening of Self-Designed Molecular Library

N Liu, Z Yang, Y Liu, X Dang, Q Zhang, J Wang… - International journal of …, 2023 - mdpi.com
There have been outbreaks of SARS-CoV-2 around the world for over three years, and its
variants continue to evolve. This has become a major global health threat. The main …

[HTML][HTML] Repurposing an antiviral drug against SARS‐CoV‐2 main protease

A Sarkar, K Mandal - Angewandte Chemie (International ed. in …, 2021 - ncbi.nlm.nih.gov
This article highlights recent pioneering work by Günther et al. towards the discovery of
potential repurposed antiviral compounds (peptidomimetic and non‐peptidic) against the …

Computer-aided screening for potential coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitory peptides from putative hemp seed trypsinized peptidome

K Prasertsuk, K Prongfa, P Suttiwanich, N Harnkit… - Molecules, 2022 - mdpi.com
To control the COVID-19 pandemic, antivirals that specifically target the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) are urgently required. The 3 …

Structure-guided design of potent inhibitors of SARS-CoV-2 3CL protease: structural, biochemical, and cell-based studies

CS Dampalla, AD Rathnayake, KD Perera… - Journal of medicinal …, 2021 - ACS Publications
The COVID-19 pandemic is having a major impact on public health worldwide, and there is
an urgent need for the creation of an armamentarium of effective therapeutics, including …

Cyclic β2,3-amino acids improve the serum stability of macrocyclic peptide inhibitors targeting the SARS-CoV-2 main protease

T Miura, TR Malla, L Brewitz, A Tumber… - Bulletin of the …, 2024 - academic.oup.com
Due to their constrained conformations, cyclic β2, 3-amino acids (cβAA) are key building
blocks that can fold peptides into compact and rigid structures, improving peptidase …